HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues
暂无分享,去创建一个
Qi Zhang | Yutian Chong | Jiao Gong | Rong Li | Yaqiong Chen | Zhenjian Zhuo | Shuru Chen | Jing Cao | Bo Hu | Y. Chong | Jing Cao | Yaqiong Chen | Qi Zhang | Zhenjian Zhuo | Bo Hu | Rong Li | Jiao Gong | Shuru Chen
[1] Y. Chong,et al. NCAPG Is a Promising Therapeutic Target Across Different Tumor Types , 2020, Frontiers in Pharmacology.
[2] Yuting He,et al. Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set , 2020, Aging.
[3] J. Bruix,et al. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects , 2010, Seminars in liver disease.
[4] S. Bae,et al. Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma , 2020, Cancers.
[5] H. Lee,et al. Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma , 2017, Molecular oncology.
[6] M. Schwartz,et al. Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C–Related Hepatocellular Carcinoma: A Retrospective Analysis of a Single North American Center , 2014, Annals of surgery.
[7] Jiuyong Li,et al. CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization , 2017, Bioinform..
[8] S. Imbeaud,et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.
[9] A. Burroughs,et al. Hepatocellular carcinoma , 2003, The Lancet.
[10] C. Ishioka,et al. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model , 2017, Cancer Immunology, Immunotherapy.
[11] V. Mazzaferro,et al. Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.
[12] Jens Nielsen,et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes , 2018, Proceedings of the National Academy of Sciences.
[13] Xin Wei Wang,et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.
[14] Y. Chong,et al. The clinical value of Fibulin-1 for prognosis and its prospective mechanism in intrahepatic cholangiocarcinoma. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[15] Lu He,et al. EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3 , 2020, Cell Death & Disease.
[16] H. Benyamini,et al. Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. , 2017, Cancer research.
[17] Stephanie Roessler,et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. , 2012, Gastroenterology.
[18] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] Y. Pomyen,et al. Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. , 2017, Cancer cell.
[20] Zhiguang Li,et al. Paradoxical Roles of IL-4 in Tumor Immunity , 2009, Cellular and Molecular Immunology.
[21] K. Hui,et al. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. , 2016, Cancer letters.
[22] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[23] X. Sang,et al. Construction of a lipid metabolism‐related and immune‐associated prognostic signature for hepatocellular carcinoma , 2020, Cancer medicine.
[24] Hongmei Sun,et al. Up-regulation of CXCL8 expression is associated with a poor prognosis and enhances tumor cell malignant behaviors in liver cancer , 2020, Bioscience reports.
[25] A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients , 2020, Journal of translational medicine.
[26] Jian Zhang,et al. Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma , 2019, Front. Oncol..
[27] D. Fan,et al. Interleukin 1β-mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP , 2020, Theranostics.
[28] K. Liestøl,et al. Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer , 2019, Modern Pathology.
[29] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[30] Gregory J. Gores,et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.
[31] Kenji Ikeda,et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.
[32] Yun Zheng,et al. A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma , 2020, International journal of biological sciences.